{"id":7507,"date":"2025-05-05T11:55:00","date_gmt":"2025-05-05T09:55:00","guid":{"rendered":"https:\/\/nanexa.com\/mfn_news\/analys-av-de-forsta-proverna-fran-30-mg-dosgruppen-i-nex-22-fas-i-studien-visar-fortsatt-lovande-resultat\/"},"modified":"2025-05-05T11:55:00","modified_gmt":"2025-05-05T09:55:00","slug":"analys-av-de-forsta-proverna-fran-30-mg-dosgruppen-i-nex-22-fas-i-studien-visar-fortsatt-lovande-resultat","status":"publish","type":"mfn_news","link":"https:\/\/nanexa.com\/sv\/mfn_news\/analys-av-de-forsta-proverna-fran-30-mg-dosgruppen-i-nex-22-fas-i-studien-visar-fortsatt-lovande-resultat\/","title":{"rendered":"Analys av de f\u00f6rsta proverna fr\u00e5n 30 mg dosgruppen i NEX-22 fas I-studien visar fortsatt lovande resultat"},"content":{"rendered":"
\n

Nanexa meddelar idag att de f\u00f6rsta farmakokinetiska (PK) proverna fr\u00e5n den sista dosgruppen, 30 mg, i den p\u00e5g\u00e5ende fas I-studien f\u00f6r NEX-22 har analyserats. Resultaten visar att PK-profilen \u00e4r lik den f\u00f6r tidigare dosgrupper och att plasmaexponeringen som f\u00f6rv\u00e4ntat \u00f6kar med \u00f6kad dos.<\/strong><\/p>\n<\/div>\n

\n

\u201dStudien av NEX-22 \u00e4r en viktig del av v\u00e5r forskning och utveckling, och dessa prelimin\u00e4ra resultat \u00e4r mycket uppmuntrande\u201d, s\u00e4ger David Westberg, vd Nanexa. \u201dResultaten indikerar att behandlingen har en f\u00f6ruts\u00e4gbar och dosberoende farmakokinetisk profil, vilket ger en bra grund f\u00f6r den kommande fas Ib-studien i NEX-22 projektet. Det \u00e4r \u00e4ven ett positivt tecken f\u00f6r utveckling av andra l\u00e5ngtidsverkande injicerbara l\u00e4kemedel med v\u00e5r PharmaShell teknologi\u201d.<\/p>\n

Vi ser fram emot att avsluta denna studie efter de sista klinikbes\u00f6ken som sker denna vecka och att dela med oss av ytterligare resultat n\u00e4r de blir tillg\u00e4ngliga.<\/p>\n<\/div>\n

\n

F\u00f6r mer information kontakta:<\/strong><\/p>\n

\n

David Westberg \u2013 VD, Nanexa AB (publ)\u00a0
Telefon: 0709-42 83 03
E-post:\u00a0david.westberg@nanexa.se<\/a>
www.nanexa.com<\/a><\/p>\n

Bolagets Certified Adviser \u00e4r Carnegie Investment Bank AB (publ).<\/p>\n<\/div>\n

\n

Om Nanexa AB (publ)<\/strong><\/p>\n

\n

Nanexa \u00e4r ett l\u00e4kemedelsbolag som utvecklar injicerbara l\u00e4kemedel baserade p\u00e5 det patenterade och innovativa drug delivery-systemet PharmaShell\u00ae \u2013 ett system som m\u00f6jligg\u00f6r n\u00e4sta generations l\u00e5ngverkande injicerbara l\u00e4kemedel med h\u00f6g drug load, tillverkade med atomlagerprecision. Nanexa utvecklar egna produkter och har dessutom samarbetsavtal med flera l\u00e4kemedelsbolag, d\u00e4ribland Novo Nordisk och AstraZeneca.<\/p>\n

Nanexas aktie \u00e4r noterad p\u00e5 Nasdaq First North Growth Market i Stockholm (NANEXA).<\/p>\n<\/div>\n

\n

Bifogade filer<\/strong><\/p>\n

\n

Analys av de f\u00f6rsta proverna fr\u00e5n 30 mg dosgruppen i NEX-22 fas I-studien visar fortsatt lovande resultat<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Nanexa meddelar idag att de f\u00f6rsta farmakokinetiska (PK) proverna fr\u00e5n den sista dosgruppen, 30 mg, i den p\u00e5g\u00e5ende fas I-studien f\u00f6r NEX-22 har analyserats. Resultaten visar att PK-profilen \u00e4r lik den f\u00f6r tidigare dosgrupper och att plasmaexponeringen som f\u00f6rv\u00e4ntat \u00f6kar med \u00f6kad dos.<\/p>\n","protected":false},"template":"","class_list":["post-7507","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ci_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn-ext-nq_sv","mfn-news-tag-mfn-ext-nq-company-announcement_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-ci-other_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"\nAnalys av de f\u00f6rsta proverna fr\u00e5n 30 mg dosgruppen i NEX-22 fas I-studien visar fortsatt lovande resultat - Nanexa AB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanexa.com\/mfn_news\/analys-av-de-forsta-proverna-fran-30-mg-dosgruppen-i-nex-22-fas-i-studien-visar-fortsatt-lovande-resultat\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Analys av de f\u00f6rsta proverna fr\u00e5n 30 mg dosgruppen i NEX-22 fas I-studien visar fortsatt lovande resultat - Nanexa AB\" \/>\n<meta property=\"og:description\" content=\"Nanexa meddelar idag att de f\u00f6rsta farmakokinetiska (PK) proverna fr\u00e5n den sista dosgruppen, 30 mg, i den p\u00e5g\u00e5ende fas I-studien f\u00f6r NEX-22 har analyserats. Resultaten visar att PK-profilen \u00e4r lik den f\u00f6r tidigare dosgrupper och att plasmaexponeringen som f\u00f6rv\u00e4ntat \u00f6kar med \u00f6kad dos.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanexa.com\/mfn_news\/analys-av-de-forsta-proverna-fran-30-mg-dosgruppen-i-nex-22-fas-i-studien-visar-fortsatt-lovande-resultat\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanexa AB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/analys-av-de-forsta-proverna-fran-30-mg-dosgruppen-i-nex-22-fas-i-studien-visar-fortsatt-lovande-resultat\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/analys-av-de-forsta-proverna-fran-30-mg-dosgruppen-i-nex-22-fas-i-studien-visar-fortsatt-lovande-resultat\\\/\",\"name\":\"Analys av de f\u00f6rsta proverna fr\u00e5n 30 mg dosgruppen i NEX-22 fas I-studien visar fortsatt lovande resultat - Nanexa AB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\"},\"datePublished\":\"2025-05-05T09:55:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/analys-av-de-forsta-proverna-fran-30-mg-dosgruppen-i-nex-22-fas-i-studien-visar-fortsatt-lovande-resultat\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/analys-av-de-forsta-proverna-fran-30-mg-dosgruppen-i-nex-22-fas-i-studien-visar-fortsatt-lovande-resultat\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/analys-av-de-forsta-proverna-fran-30-mg-dosgruppen-i-nex-22-fas-i-studien-visar-fortsatt-lovande-resultat\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Analys av de f\u00f6rsta proverna fr\u00e5n 30 mg dosgruppen i NEX-22 fas I-studien visar fortsatt lovande resultat\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"name\":\"Nanexa AB\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanexa.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\",\"name\":\"Nanexa AB\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"contentUrl\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"width\":165,\"height\":50,\"caption\":\"Nanexa AB\"},\"image\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Analys av de f\u00f6rsta proverna fr\u00e5n 30 mg dosgruppen i NEX-22 fas I-studien visar fortsatt lovande resultat - Nanexa AB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanexa.com\/mfn_news\/analys-av-de-forsta-proverna-fran-30-mg-dosgruppen-i-nex-22-fas-i-studien-visar-fortsatt-lovande-resultat\/","og_locale":"sv_SE","og_type":"article","og_title":"Analys av de f\u00f6rsta proverna fr\u00e5n 30 mg dosgruppen i NEX-22 fas I-studien visar fortsatt lovande resultat - Nanexa AB","og_description":"Nanexa meddelar idag att de f\u00f6rsta farmakokinetiska (PK) proverna fr\u00e5n den sista dosgruppen, 30 mg, i den p\u00e5g\u00e5ende fas I-studien f\u00f6r NEX-22 har analyserats. Resultaten visar att PK-profilen \u00e4r lik den f\u00f6r tidigare dosgrupper och att plasmaexponeringen som f\u00f6rv\u00e4ntat \u00f6kar med \u00f6kad dos.","og_url":"https:\/\/nanexa.com\/mfn_news\/analys-av-de-forsta-proverna-fran-30-mg-dosgruppen-i-nex-22-fas-i-studien-visar-fortsatt-lovande-resultat\/","og_site_name":"Nanexa AB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"1 minut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nanexa.com\/mfn_news\/analys-av-de-forsta-proverna-fran-30-mg-dosgruppen-i-nex-22-fas-i-studien-visar-fortsatt-lovande-resultat\/","url":"https:\/\/nanexa.com\/mfn_news\/analys-av-de-forsta-proverna-fran-30-mg-dosgruppen-i-nex-22-fas-i-studien-visar-fortsatt-lovande-resultat\/","name":"Analys av de f\u00f6rsta proverna fr\u00e5n 30 mg dosgruppen i NEX-22 fas I-studien visar fortsatt lovande resultat - Nanexa AB","isPartOf":{"@id":"https:\/\/nanexa.com\/#website"},"datePublished":"2025-05-05T09:55:00+00:00","breadcrumb":{"@id":"https:\/\/nanexa.com\/mfn_news\/analys-av-de-forsta-proverna-fran-30-mg-dosgruppen-i-nex-22-fas-i-studien-visar-fortsatt-lovande-resultat\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanexa.com\/mfn_news\/analys-av-de-forsta-proverna-fran-30-mg-dosgruppen-i-nex-22-fas-i-studien-visar-fortsatt-lovande-resultat\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nanexa.com\/mfn_news\/analys-av-de-forsta-proverna-fran-30-mg-dosgruppen-i-nex-22-fas-i-studien-visar-fortsatt-lovande-resultat\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/nanexa.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/nanexa.com\/mfn_news\/"},{"@type":"ListItem","position":3,"name":"Analys av de f\u00f6rsta proverna fr\u00e5n 30 mg dosgruppen i NEX-22 fas I-studien visar fortsatt lovande resultat"}]},{"@type":"WebSite","@id":"https:\/\/nanexa.com\/#website","url":"https:\/\/nanexa.com\/","name":"Nanexa AB","description":"","publisher":{"@id":"https:\/\/nanexa.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanexa.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/nanexa.com\/#organization","name":"Nanexa AB","url":"https:\/\/nanexa.com\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","contentUrl":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","width":165,"height":50,"caption":"Nanexa AB"},"image":{"@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news\/7507","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/media?parent=7507"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}